Patel et al 1 are to be congratulated for demonstrating excellent outcomes in their patients treated with transoral laser microsurgery (TLM) and adjuvant therapy. However, it is important to stress that the conclusion should have read "TLM followed by radiotherapy (RT) for selected patients with advanced oropharyngeal cancer results in excellent control rates," as this retrospective study has clear selection bias. The study design would have been far more interesting (and novel in comparison to other TLM/transoral robotic surgery [TORS] series) had the authors queried their registry for all previously untreated patients with oropharyngeal cancer, so the reader could better understand how many stage 3 and 4 patients were dispositioned for this therapy. Granted, as a center of excellence for this surgery, there might still be bias, as >50% of patients from their initial search had stage I and II disease, so their population might reflect patients who actively seek their surgical expertise.
The authors' comparison with one chemoradiation series (Setton et al 2 ) further highlights this patient selection. The caveat that more patients in the Memorial Sloan-Kettering Cancer Center study had T3/T4 disease is correct, but understates the difference, as Patel et al only had 9% T3 patients and no T4 patients. Patel et al also correctly point out that the majority of patients in the Memorial Sloan-Kettering Cancer Center study had T1/ T2 disease, but the percent of T1 patients was only 27%, compared to 53% in the current article. T1 node-positive patients are nominally stage 3 and 4, but most chemoradiation studies have either excluded these patients or have very few patients with this low tumor burden, and these patients can be treated effectively with radiation with or without neck dissection. 3 Additionally, although the authors discuss a prior experience with TLM alone for stage 3 and 4 patients, those patients were highly selected, included patients who refused adjuvant treatment, and only 9 had N2b disease or greater.
Patel et al also described a 1-year gastrostomy rate of >6%, "comparable to rates described in definitive chemoradiation series." This was despite eliminating chemotherapy in half the patients, and focusing on the neck only in nearly one third of patients. Because only some patients had this significant deintensification, there are 2 possibilities. Either there was no benefit, as the rate was consistent for all patients regardless of modifications, or those who had less therapy had lower rates of tubes, suggesting that those who were not suitable for treatment modifications after surgery had higher rates. Put simply, if patients receiving TLM followed by RT have gastrostomy rates that are not demonstrably improved from radiotherapy alone, why add surgery in the absence of perceived oncologic benefit?
Thus, deintensification strategies should not be limited to only identifying those patients for whom the adjuvant therapy dose may be reduced, but also clearly selecting which patients will benefit most from adding surgery to their management. For example, many no longer advocate planned neck dissections post-chemoradiation. 4 However, the question of the role of the upfront neck dissection remains unanswered, yet it seems from the current series and others, that despite the emphasis on TLM (as reflected in the title and conclusions), that neck dissection is the principle driver of decisions regarding adjuvant therapy in these patients with stage 3 and 4 disease.
TLM and TORS have been established as effective oncologic treatments, and are positive additions to our therapies to treat oropharyngeal cancer, as reflected in the current series. Unfortunately, the current staging system has too broad a definition of stage 4. It is specious, for example, to equate gastrostomy probabilities from patients with T1N2aM0 oropharyngeal cancer (who might be excellent candidates for therapy deintensification by TLM 1 RT or RT alone) with patients who have T4N2cM0 requiring chemoradiation, as if both are likely to achieve comparable outcomes, either in local control or therapy-attributable toxicity. 5 Consequently, we recommend re-evaluation of current staging practices, as they are inadequate for modern oropharynx patient populations. 6 Excellent oncologic results can be obtained with TLM and TORS in well-selected cohorts, and efforts, such as Patel et al, are to be applauded for continuing to define the potential parameters and clinical endpoints of interest for such approaches in future prospective trials. In the meantime, it is essential that articles focusing on TLM and TORS define which subgroups of patients with "advanced oropharyngeal cancer" they have selected for these therapies, in order that we may, by strenuous avoidance of "straw man" comparisons, cogently select those patients with oropharyngeal cancer with maximal probability of therapeutic gain from these exciting technologies. 4 . Ferlito A, Corry J, Silver CE, Shaha AR, Thomas Robbins K, Rinaldo A.
Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. 
To the Editor:
We thank Garden et al 1 for their constructive comments and take the opportunity to respond to several issues.
In regard to study design, there is a clear predisposition for patients to seek transoral surgery secondary to our site being known as a center of excellence. Our long track record of treating oropharyngeal cancer with upfront surgery, especially with transoral laser microsurgery, 2 has been delineated in prior reports. In this particular study, we delineated a portion of our experience in which patients completed all of their adjuvant therapy at our institution. All patients are scheduled consultations with radiation oncologists to learn of nonsurgical treatment options.
In this era of human papillomavirus-related tumors, most patients presenting with stage 3 and 4 disease are presenting with low volume T classification with nodal disease. Stage 3 and 4 disease is indeed heterogeneous and we agree that bulky T3 and T4 disease may not be suitable for transoral surgical techniques. One caveat is that not all T3 and T4 disease is equal. Patients may present with mainly exophytic tumors that qualify as T3 or T4 disease but could still be amenable to transoral surgery.
Because our study spans more than a decade, 2 of the 5 patients with gastrostomy tubes received 3D conformal radiation therapy and all patients had radiation to their primary site. Respecting long established guidelines for adjuvant radiation therapy (RT), 3 our treatment deintensification in regard to considering modification of radiation treatment fields (exclusion of the primary site) is only a recent development. Only through careful review of margins through our multidisciplinary team and lack of adverse risk factors, such as perineural invasion and lymphovascular invasion, are we considering such RT field modifications. A modern reinterpretation of indications for adjuvant therapy is necessary in human papillomavirus-related tumors. As outlined in the article, adjuvant RT doses and fields could differ and needs prospective study. Also, the role of adjuvant chemotherapy is under question. Prospective studies, such as the Adjuvant De-escalation, Extracapsular Spread, P161, Transoral (ADEPT) trial randomizing stage 3 and 4 patients undergoing transoral surgery with nodal extracapsular spread between adjuvant radiation with or without chemotherapy, will provide further insight.
Prospective study is still needed in identifying optimal deintensification strategies. Although there certainly is focus on alteration of RT doses and fields and chemotherapy regimens, the role of neck dissection needs to be further clarified when adjuvant RT is definitely indicated. One important point is that not all neck dissections are equal and selective neck dissections are now frequently used in lieu of more radical dissections.
Having one of the longest experiences using transoral surgery for oropharyngeal cancer, our institutional results provide selected stage 3 and 4 patients with treatment options. Current data suggests comparable clinical outcomes between surgical and nonsurgical approaches. 4 Emerging quality of life data seems promising between the 2 approaches as well and needs to be studied prospectively in order to effectively utilize the latest advances in surgery and RT. 5, 6 We remain committed to provide patients with all treatment options through our multidisciplinary head and neck team.
